Charles Schwab
HURA

Charles Schwab’s TuHURA Biosciences HURA Stock Holding History

Charles Schwab’s Portfolio HURA Stock Details HURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-98,937
Closed -$177K – 3578
2026
Q1 		$177K Buy
98,937
+17,017
+21% +$20.9K ﹤0.01% 3316
2025
Q4 		$62K Buy
81,920
+2,888
+4% +$5.53K ﹤0.01% 3416
2025
Q3 		$196K Hold
79,032
– – ﹤0.01% 3349
2025
Q2 		$176K Buy
79,032
+64,032
+427% +$216K ﹤0.01% 3387
2025
Q1 		$48.5K Hold
15,000
– – ﹤0.01% 3405
2024
Q4 		$61.4K Buy
+15,000
New +$79.7K ﹤0.01% 3432

Other funds holding HURA

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Charles Schwab's HURA Position: Q2 2026 in Review

Charles Schwab sold out of TuHURA Biosciences (HURA) in Q2 2026, closing a stake of 98,937 shares — an estimated $177K sold.

Charles Schwab first reported a position in HURA in Q4 2024 and held it in 6 quarters. The position peaked at $196K in Q3 2025. 90 funds tracked by Wall St. Rank hold HURA as of Q2 2026.

  • Charles Schwab reported no remaining TuHURA Biosciences position as of Q2 2026 after selling out during the quarter.
  • Charles Schwab sold 98,937 TuHURA Biosciences shares in Q2 2026, an estimated $177K.
  • Charles Schwab first reported a position in TuHURA Biosciences in Q4 2024 and held it in 6 quarters.
  • Charles Schwab's TuHURA Biosciences position peaked at $196K in Q3 2025.
  • 90 funds tracked by Wall St. Rank held TuHURA Biosciences as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.